Literature DB >> 7563343

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

M J Barry1, W O Williford, Y Chang, M Machi, K M Jones, E Walker-Corkery, H Lepor.   

Abstract

PURPOSE: We assessed the relationship between changes in scores for the American Urological Association (AUA) symptom index and benign prostatic hyperplasia (BPH) impact index with patient global ratings of improvement in a large Veterans Affairs trial comparing different pharmacological therapies for BPH.
MATERIALS AND METHODS: The primary analyses compared absolute score changes from baseline with global ratings of improvement at 13 weeks for 1,218 men.
RESULTS: Subjects who rated themselves as being slightly improved had a mean decrease in AUA symptom index and BPH impact index scores of 3.1 and 0.4 points, respectively. However, the baseline scores strongly influenced this relationship.
CONCLUSIONS: These data provide guidance for investigators using the AUA symptom index and BPH impact index as outcome measures.

Entities:  

Mesh:

Year:  1995        PMID: 7563343     DOI: 10.1016/s0022-5347(01)66780-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  127 in total

Review 1.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Optimizing the management of benign prostatic hyperplasia.

Authors:  Dean S Elterman; Jack Barkin; Steven A Kaplan
Journal:  Ther Adv Urol       Date:  2012-04

3.  Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.

Authors:  Michael J Barry; Sreelatha Meleth; Jeannette Y Lee; Karl J Kreder; Andrew L Avins; J Curtis Nickel; Claus G Roehrborn; E David Crawford; Harris E Foster; Steven A Kaplan; Andrew McCullough; Gerald L Andriole; Michael J Naslund; O Dale Williams; John W Kusek; Catherine M Meyers; Joseph M Betz; Alan Cantor; Kevin T McVary
Journal:  JAMA       Date:  2011-09-28       Impact factor: 56.272

Review 4.  Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials.

Authors:  Igor Sorokin; Adam Schatz; Charles Welliver
Journal:  Curr Urol Rep       Date:  2015-10       Impact factor: 3.092

5.  Self management for men with lower urinary tract symptoms: randomised controlled trial.

Authors:  Christian T Brown; Tet Yap; David A Cromwell; Lorna Rixon; Liz Steed; Kathleen Mulligan; Anthony Mundy; Stanton P Newman; Jan van der Meulen; Mark Emberton
Journal:  BMJ       Date:  2006-11-21

6.  Best of the 2002 AUA Annual Meeting: Highlights of the 2002 Annual Meeting of the American Urological Association May 25-30, 2002, Orlando, FL.

Authors: 
Journal:  Rev Urol       Date:  2002

7.  Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto.

Authors:  Jeannette Y Lee; Page Moore; John Kusek; Michael Barry
Journal:  J Altern Complement Med       Date:  2013-02-05       Impact factor: 2.579

8.  Effect of tension-free vaginal tape and TVT-obturator on lower urinary tract symptoms other than stress urinary incontinence.

Authors:  Katie N Ballert; Jamie A Kanofsky; Victor W Nitti
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-09-14

Review 9.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

10.  Dependence of the minimal clinically important improvement on the baseline value is a consequence of floor and ceiling effects and not different expectations by patients.

Authors:  Michael M Ward; Lori C Guthrie; Maria Alba
Journal:  J Clin Epidemiol       Date:  2014-02-17       Impact factor: 6.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.